NewLink Genetics Corporation (NASDAQ:NLNK) major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the business’s stock in a transaction dated Friday, October 6th. The stock was acquired at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NewLink Genetics Corporation (NASDAQ NLNK) traded down 7.20% during trading on Friday, reaching $10.70. The company had a trading volume of 2,398,061 shares. The firm’s 50 day moving average price is $10.14 and its 200 day moving average price is $11.79. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The firm’s market capitalization is $314.80 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. Equities research analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/newlink-genetics-corporation-nlnk-major-shareholder-stine-seed-farm-inc-buys-780487-shares-of-stock/1615873.html.

A number of hedge funds have recently modified their holdings of NLNK. Columbus Circle Investors boosted its holdings in NewLink Genetics Corporation by 72.5% in the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after purchasing an additional 248,724 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in NewLink Genetics Corporation in the first quarter worth approximately $5,127,000. Ameriprise Financial Inc. purchased a new stake in NewLink Genetics Corporation in the first quarter worth approximately $3,453,000. Marshall Wace North America L.P. purchased a new stake in NewLink Genetics Corporation in the first quarter worth approximately $2,578,000. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in NewLink Genetics Corporation in the first quarter worth approximately $2,578,000. Institutional investors own 54.78% of the company’s stock.

A number of brokerages have recently weighed in on NLNK. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research note on Monday, September 25th. ValuEngine upgraded NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. Stifel Nicolaus boosted their target price on NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Finally, Jefferies Group LLC upgraded NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. NewLink Genetics Corporation has an average rating of “Buy” and an average price target of $26.60.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.